DLC2 Protein and Its Role in Liver Cancer Prognosis
Author Information
Author(s): Xiaorong Li, Wei Wu, Liyuan Qian, Kaiyan Yang
Primary Institution: The Third Affiliated Hospital of Central South University
Hypothesis
Does DLC2 protein underexpress in hepatocellular carcinoma and correlate with RhoA expression and clinicopathological parameters?
Conclusion
Decreased DLC2 expression in HCC correlates with poor prognosis and overexpression of RhoA.
Supporting Evidence
- DLC2 protein levels were significantly lower in HCC tissues compared to pericarcinomatous liver tissues.
- HCC patients with DLC2-negative expression had a mean overall survival of 414 days, significantly lower than those with DLC2-positive expression (697 days).
- There was a significant correlation between underexpression of DLC2 and poor cell differentiation in HCC.
Takeaway
This study found that lower levels of a protein called DLC2 in liver cancer are linked to worse outcomes for patients.
Methodology
Western blot and immunohistochemical staining were used to detect DLC2 protein expression in HCC specimens.
Limitations
Some cases showed negative staining for DLC2 despite being detected in other methods, indicating potential detection sensitivity issues.
Participant Demographics
53 patients with primary hepatocellular carcinoma (46 male, 7 female), median age 55 years.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website